new Risk Evaluation and Mitigation Strategy (REMS) to reduce the misuse of long-acting opioids
FDA will encourage you to participate in a new Risk Evaluation and Mitigation Strategy (REMS) to reduce the misuse of long-acting opioids.
Unintentional deaths due to opioids have quadrupled in 8 years...and treatment for opioid abuse has increased five-fold in 10 years.
Now FDA will require manufacturers to come up with a REMS plan by mid-August...with the changes rolled out by early 2012.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote